Irinotecan and cisplatin in upper gastrointestinal malignancies

ONCOLOGY

Volumn 12, Issue 8 SUPPL., 1998, Pages 110-113

  Enzinger, Peter C ^a   Ilson, David H ^a,b   Saltz, Leonard B ^a,b   O'Reilly, Eileen M ^a,b   Kelsen, David P ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Obstetrics Gynecology

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EXATECAN; FLUOROURACIL; IRINOTECAN; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ESOPHAGUS CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEPHROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; STOMACH CANCER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CISPLATIN; DRUG THERAPY, COMBINATION; GASTROINTESTINAL NEOPLASMS; HUMANS;

EID: 0031797401     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Chen AY, Liu LF: DNA topoisomerases: Essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol 34:191-218, 1994.
2. Hsiang YH, Hertzberg R, Hecht S: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14.873-878, 1985.
3. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1,722-726, 1988.
4. Creemers CJ, Lund B, Verwij J: Topoisomerase I inhibitors. Topotecan and irinotecan. Cancer Treat I Rev 20:73-96, 1994.
5. Wall ME, Wani MC, Cook CE: Plant antitumor agents: I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88(3):888-890, 1966.
6. Gottleib JA, Guarino AM, Call JB: Preliminary and pharmacologic and clinical evaluation of camptothecin sodium. Cancer Chemother Rep 54:461-470, 1970.
7. Tsuji T, Kaneda N, Kado K. CPT-11 converting enzyme from rat serum: Purification and some properties. J Pharmacobiodyn 14:341-349, 1992.
8. Rothenberg ML, Kuhn JG, Burris HAI: Phase I and pharmacokinetic trial of weekly CPT-11 J Clin Oncol 11:2194-2204, 1993.
9. Kawato Y, Aonuma M, Hirota Y. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the anti-tumor effect of CPT-11. Cancer Res 51:4187-4191, 1991.
10. Mitsui I, Kumazawa E, Hirota Y: A new water soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 86:776-782, 1995.
11. Ikeda K, Terashima M, Yqegashi Y Antitumor activities of camptothecin analogs against human esophageal cancer. Proc Am Assoc Cancer Res 36:2702, 1995.
12. Masumoto N, Nakano S, Esaki T: Inhibition of cis-diamminedichloroplatinum (II)- induced DNA interstrand cross-link removal by 7-cthyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer 62:70-75, 1995.
13. Masumoto N, Nakano S, Esaki T: Sequence-dependent modulation of anticancer drug activities by 7-ethy 1-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. Anntcancer Res 15:405-410, 1995.
14. Masuda N, Fukuoka M, Kudoh S: Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced nonsmall-cell lung cancer J Clin Oncol 12:90-96, 1994.
15. Masuda N, Fukuoka M, Kudoh S: Phase 1 and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68:777-782, 1993.
16. Mori K, Suga U, Kishiro I: A phase I study of CPT-11 and cisplatin (5 day continuous infusion) for advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 13:366, 1994.
17. Nitta T, Takada M, Hirashima T: Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Proc Am Assoc Cancer Res 34:206, 1993.
18. Kambe M, Wakui A, Nakao I, et al: A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancers. Proc Am Soc Clin Oncol 12:584, 1993.
19. Shirao K, Shimada Y, Kondo H, et al: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921-927, 1997.
20. Boku N, Ohtsu Y, Shimada K, et al: Phase II study of a combination of CDDP and CPT-11 in metastatic gastric cancer: CPT-11 study group for gastric cancer. Proc Am Soc Clin Oncol 16:936, 1997.
21. Saltz L, Kanowitz J, Kelsen D, et al: Phase I study of weekly cisplatin (CDDP) plus irinotecan (CRT-11) in patients (PTS) with advanced solid tumors. Proc Am Soc Clin Oncol 15:1540, 1996.
22. Rowinsky E, Gilbert M, McGuire W, et al: Sequences of Taxol and cisplatin A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991.
23. Frasci G, Cornelia P, Parziale A, et al: Cisplatin-paclitaxel weekly schedule in advanced solid tumors: Phase I study. Ann Oncol 8:291-293, 1997.
24. Couteau C, Lokiec F, Vernillet L, et al: Phase I dose-finding and pharmacokinetic (PK) study of docetaxel (D) in combination with irinotecan (I) in advanced solid tumors. Proc Am Soc Clin Oncol 16:709, 1997.
25. Debernardis D, Cimoli G, Parodi S, et al: Interactions between Taxol and camptothecin Anticancer Drug Des 7:531-534, 1996.
26. Lilenbaum R, Ratain M, Miller A, et al: Phase I study of paclitaxel and topotecan in patients with advanced tumors: A Cancer and Leukemia Group B study. J Clin Oncol 13:2230-2237, 1995.
27. Saltz L, Kanowitz J, Kemeny NE, et al: Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 14:2959-2967, 1996.